In Vivo Studies of Radiolabeled Monoclonal Antibodies Mc5 and KC4 in Human Breast Cancer

  • Paul A. BunnJr.
  • David G. Dienhart
  • Raymond F. Schmelter
  • James L. Lear
  • Gary Miller
  • Duane C. Bloedow
  • Cliff Longley
  • Philip Furmanski
  • Roberto L. Ceriani

Abstract

Breast cancer is the most common malignancy in women in the United States, with over 130,000 new cases developing annually(1). Despite improved methods for early detection and treatment, the death rate from breast cancer in the United States has not changed over tbe past 25 years. Nearly all patients who die from breast cancer do so as a result of widespread systemic metastases. Metastatic breast cancer is difficult to detect early and impossible to cure with currently available treatment modalities.

Keywords

Breast Cancer Nude Mouse Tumor Uptake Athymic Nude Mouse Murine Monoclonal Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    E. Silverberg and J. A. Lubera, Cancer statistics,Ca — A Journal for Clinicians. 38:5–22(1988).CrossRefGoogle Scholar
  2. 2.
    R.L. Ceriani, K.E. Thompson, J.A. Peterson, and S. Abrahm, Surface differentiation antigens of human mammary epithelial cells carried on the human milk fat globule. Proc. Natl. Acad. Sci(USA) 74:582–586(1977).CrossRefGoogle Scholar
  3. 3.
    J. Arklie, J. Taylor-Papadimitriou, W. F. Bodner, M. Eagan, and R. Mills, Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancer,Int. J. Cancer 28:23–29(1981).PubMedCrossRefGoogle Scholar
  4. 4.
    D. Hofheinz, D. Dienhart, G. Miller,et al., Monoclonal antibody, KC4G3, recognizes a novel, widely expresssed antigen on human epithelial cancers,Proc. Am. Assoc. Cancer. Res. 28:1552(1987).Google Scholar
  5. 5.
    R. L. Ceriani, J. A. Peterson, L. Y. Lee, F. R. Moncada, and E. W. Blank, Characterization of cell surface antigens of human mammary epithelial cells with monoclonal antibodies prepared against human milk fat globule,Som. Cell Genet. 9:415–527(1983).CrossRefGoogle Scholar
  6. 6.
    J. Taylor-Papadimitriou, J. A. Peterson, J. Arklie, J. Burchell, R. L. Ceriani, and W. F. Bodner, Monoclonal antibodies to epithelium-specific components of human milk fat globule membrane production and reaction with cells in culture,Int. J. Cancer. 28:17–24(1981).PubMedCrossRefGoogle Scholar
  7. 7.
    R. L. Ceriani, E.H. Rosenbaum, M. Chandler, T.T. Trujillo, B. Myers and M. Sakada, Role of circulating human mammary epithelial antigens(HME-Ags) as serum markers for breast cancer. In “Tumor markers and their significance in the management of breast cancer.” IP, C.. ed. A.R. Liss. ed.. 1986. pp.3–19.Google Scholar
  8. 8.
    F. C. Greenwood, W. M. Hunter and J.S. Glover, The preparation of 131-I-labeled human growth hormone of high specific activity,Biochem J. 89:114–119(1963).PubMedGoogle Scholar
  9. 9.
    T. Lindmo, E. Boven, F. Cuttitta, J. Fedorko, and P.A. Bunn Jr., Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess,J. Immunol. Methods. 72:77–86(1984).PubMedCrossRefGoogle Scholar
  10. 10.
    R. D. Brown and J. E. Manno, ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimations in pharmacokinetics,J. Pharm. Sci. 67:1687–1691(1979).CrossRefGoogle Scholar
  11. 11.
    H. G. Boxenbaum, S. Riegelman, and R. M. Elashoff, Statistical estimations in pharmacokinetics,J. Pharmacokinet. Biopharmaceut. 2:123–148(1974).Google Scholar
  12. 12.
    A. H. Epenetos, S. Mather, M. Granowska,et al., Targeting of iodine-123-labeled tumor-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumors,Lancet 2:99–1006(1982).Google Scholar
  13. 13.
    R. M. Rainsbury, J. H. Westwood, R. C. Coomlees, and A. M. Neville, Location of metastatic breast carcinoma by a monoclonal antibody chelate labeled with indium-111,Lancet 2:934–938(1983).PubMedCrossRefGoogle Scholar
  14. 14.
    H. P. Kalofonos, G. B. Sivolopenko, N. I. Courteney-Luck,et al., Antibody guided targeting of non-small cell lung cancer using 111-In-labeled HMFG1 F(ab’)2 fragments,Cancer Res 48:1977–1984(1988).PubMedGoogle Scholar
  15. 15.
    A. A. Epenetos, D. Snook, H. Durbin, P. M. Johnson, and J. Taylor-Papadimitriou, Limitation of radiolabeled monoclonal antibodies for localization of human neoplasms,Cancer Res. 46:3183–3191(1986).PubMedGoogle Scholar
  16. 16.
    M. Granowska, K. E. Britton, J. H. Shepherd,et al., A prospective study of 123Ilabeled monoclonal antibody imaging in ovarian cancer,J. Clin. Oncol. 4:730–736(1986).PubMedGoogle Scholar
  17. 17.
    D. Dienhart, R. Schmelter, J. Lear,et al., Imaging and treatment of non-small cell lung cancer with monoclonal antibody KC4G3,Proc. Am. Soc. Clin. Oncol. 6:184(1987).Google Scholar
  18. 18.
    S. T. Rosen, A. M. Zimmer, R. Goldman,et al., Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using 131-I labeled monoclonal antibody: An Illinois Cancer Council study,J. Clin. Oncol. 5:562–573(1987).PubMedGoogle Scholar
  19. 19.
    S. E. Order, G. B. Stillwagon, J. L. Klein,et al., Iodine 131 antiferritin, a new treatment modality in hepatoma: A radiation therapy oncology group study, J. Clin. Oncol. 3:1573–1582(1985).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Paul A. BunnJr.
    • 1
    • 5
  • David G. Dienhart
    • 1
    • 5
  • Raymond F. Schmelter
    • 2
    • 5
  • James L. Lear
    • 2
    • 5
  • Gary Miller
    • 3
    • 5
  • Duane C. Bloedow
    • 4
    • 5
  • Cliff Longley
    • 5
  • Philip Furmanski
    • 5
  • Roberto L. Ceriani
    • 6
  1. 1.Division of Medical Oncology, Department of MedicineUniversity of Colorado Health Sciences CenterUSA
  2. 2.Department of RadiologyUniversity of Colorado Health Sciences CenterUSA
  3. 3.Department of PathologyUniversity of Colorado Health Sciences CenterUSA
  4. 4.School of PharmacyUniversity of Colorado Health Sciences CenterUSA
  5. 5.AMC Cancer Research CenterUniversity of Colorado Cancer CenterUSA
  6. 6.John Muir Cancer and Aging Research InstituteUSA

Personalised recommendations